Page last updated: 2024-10-31

mitoxantrone and Primary Peritonitis

mitoxantrone has been researched along with Primary Peritonitis in 4 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."6.67Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies."2.67Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994)
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."2.67Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"Mitoxantrone (MXN) has demonstrated therapeutic efficacy in the intraperitoneal treatment of malignancies."1.30Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone. ( Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H; Wölfl, G, 1999)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oza, AM1
ten Bokkel Huinink, W1
Dubbelman, R1
Soepenberg, O1
Mandjes, I1
Aartsen, E1
McVie, JG1
Dufour, P1
Bergerat, JP1
Barats, JC1
Giron, C1
Duclos, B1
Dellenbach, P1
Ritter, J1
Renaud, R1
Audhuy, B1
Oberling, F1
Tarraza, HM1
Boyce, CR1
Smith, WG1
Jones, MA1
Luftensteiner, CP1
Schwendenwein, I1
Eichler, HG1
Paul, B1
Wölfl, G1
Viernstein, H1

Trials

2 trials available for mitoxantrone and Primary Peritonitis

ArticleYear
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:4

    Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito

1994
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Cancer, 1994, Apr-01, Volume: 73, Issue:7

    Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1994

Other Studies

2 other studies available for mitoxantrone and Primary Peritonitis

ArticleYear
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Gynecologic oncology, 1993, Volume: 50, Issue:3

    Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter

1993
Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone.
    International journal of pharmaceutics, 1999, Apr-15, Volume: 180, Issue:2

    Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Eating; Female; Humans; Injections, I

1999